Key facts
- Clyra Medical Technologies’s last known valuation is $56.8M (Dec 2023).
- It has raised $10.3M; the latest was PE Growth/Expansion in Sep 2025.
- Notable investors include Wychwood Holdings, Biolargo, Sanatio Capital, Tampa Bay Technology Incubator.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Clyra Medical Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Clyra Medical Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clyra Medical Technologies
Developer of wound care and surgical solutions designed to treat infections and promote wound healing while reducing the need for antibiotics. The company offers copper-iodine complex technology, that are intended to provide broad-spectrum antimicrobial efficacy against bacteria, viruses, and fungi, enabling healthcare professionals to improve patient outcomes and provide cost-effective solutions.
- Sector
- Healthcare
- HQ
- Tampa, FL, United States
- Founded
- 2012
- Employees
- 14
- Website
- clyramedical.com/
- Ownership
- Privately Held (backing)
Clyra Medical Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clyra Medical Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clyra Medical Technologies in its N-PORT filings yet. We sweep new filings monthly.